Health Care • Biotechnology: Pharmaceutical Preparations
$68.35 ▼ -0.31
(-0.45%)
MKT CAP: $224.8M • VOL: 33.5K
52W L $29 52W H $98
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$57
MEDIAN
$77
MEAN
$78
HIGH
$93
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SLGL TAPE
SLGL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $82.70 | $78.60 | 2025-02-14 | $62.20 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $86.12 | $80.65 | 2025-02-06 | $64.25 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $77.92 | $75.19 | 2025-01-29 | $65.62 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $69.72 | — | 2025-01-17 | $66.98 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $60.15 | $64.93 | 2025-01-09 | $60.83 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $81.34 | $71.08 | 2024-12-18 | $59.46 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $66.30 | $69.03 | 2024-12-04 | $63.57 | -4.3% | 48% | C |